The MW1 antibody (DSHB catalog ID: MW1), developed against the huntingtin protein, specifically recognizes expanded polyQ repeats in mutant HTT. These repeats are pathogenic hallmarks of Huntington’s disease and related polyglutamine disorders .
Epitope: Binds to the N-terminal region of HTT, conformational specificity for elongated polyQ tracts (≥20 repeats) .
MW1 is critical for identifying soluble mutant HTT in cellular and animal models. Its ability to distinguish expanded polyQ tracts enables quantification of pathogenic HTT levels .
Used in time-resolved Förster resonance energy transfer (TR-FRET) assays to monitor HTT aggregation dynamics .
Studies suggest MW1’s epitope accessibility decreases as polyQ aggregates mature, highlighting challenges in targeting late-stage aggregates .
Preclinical models using MW1 have informed therapeutic strategies aimed at clearing toxic HTT species .
Here’s a structured collection of FAQs tailored for researchers working with HTT1 antibodies, organized by complexity and grounded in methodological rigor:
Strategies:
Assay cross-validation: Compare IHC, immunofluorescence, and subcellular fractionation + immunoblotting .
Epitope mapping: Confirm the antibody’s target region (e.g., N-terminal vs. C-terminal epitopes) using truncation mutants .
Context-dependent validation: Assess tissue-specific post-translational modifications affecting antibody binding .
Considerations:
Host species compatibility: Use HTT1 antibodies raised in species distinct from other targets (e.g., rabbit HTT1 + mouse β-actin) .
Cross-reactivity screening: Pre-adsorb antibodies against off-target proteins in the panel .
Signal separation: Employ fluorophores/HRP substrates with non-overlapping emission spectra .
Resources:
Root causes:
Mitigation:
Steps: